Trial Profile
Immunogenicity of the HPV-6, 11, 16, 18 Vaccine Among Adolescent Girls Who Receive Vaccine Doses at Non-recommended Intervals and Factors Related to Non-adherence.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2018
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics
- 25 Oct 2018 Status changed from recruiting to completed.
- 07 Feb 2018 Results published in the Vaccine.
- 07 Feb 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.